These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 36385974)

  • 1. A Case of Dulaglutide-Induced Acute Interstitial Nephritis After Many Years of Treatment With an Alternate GLP-1 Receptor Agonist.
    Komala MG; Renthawa J
    Clin Diabetes; 2022; 40(4):508-510. PubMed ID: 36385974
    [No Abstract]   [Full Text] [Related]  

  • 2. Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57).
    Ishigaki Y; Strizek A; Aranishi T; Arai N; Imaoka T; Cai Z; Maegawa H
    Diabetes Ther; 2021 Jan; 12(1):345-361. PubMed ID: 33300091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dulaglutide, a GLP-1 receptor agonist, for the treatment of type 2 diabetes.
    Clements J; Moore K; Shealy K
    Expert Rev Endocrinol Metab; 2015 Nov; 10(6):581-590. PubMed ID: 30289034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A glycosylated Fc-fused glucagon-like peptide-1 receptor agonist exhibits equivalent glucose lowering to but fewer gastrointestinal side effects than dulaglutide.
    An IB; Byun MS; Yang SI; Choi Y; Woo JW; Jang HC; Sung YC
    Diabetes Obes Metab; 2020 Aug; 22(8):1455-1468. PubMed ID: 32314505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis.
    Zimner Rapuch S; Divino V; Norrbacka K; Boye K; Lebrec J; Rosilio M; DeKoven M; Guerci B
    Diabetes Ther; 2021 May; 12(5):1553-1567. PubMed ID: 33864629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerability and Effectiveness of Switching to Dulaglutide in Patients With Type 2 Diabetes Inadequately Controlled With Insulin Therapy.
    Kim Y; Huh JH; Lee M; Kang ES; Cha BS; Lee BW
    Front Endocrinol (Lausanne); 2022; 13():880164. PubMed ID: 35784534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes.
    Thompson AM; Trujillo JM
    Ann Pharmacother; 2015 Mar; 49(3):351-9. PubMed ID: 25565404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist, Dulaglutide, on Metabolic Parameters in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study.
    Katsuyama H; Hakoshima M; Umeyama S; Iida S; Adachi H; Yanai H
    Biomedicines; 2023 Mar; 11(3):. PubMed ID: 36979848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Semaglutide Versus Dulaglutide on Epicardial Fat Thickness in Subjects with Type 2 Diabetes and Obesity.
    Iacobellis G; Villasante Fricke AC
    J Endocr Soc; 2020 Apr; 4(4):bvz042. PubMed ID: 32190806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the GLP-1 Receptor Agonist Dulaglutide on the Structure of the Exocrine Pancreas of Cynomolgus Monkeys.
    Vahle JL; Byrd RA; Blackbourne JL; Martin JA; Sorden SD; Ryan T; Pienkowski T; Rosol TJ; Snyder PW; Klöppel G
    Toxicol Pathol; 2015 Oct; 43(7):1004-14. PubMed ID: 26059826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia.
    Malkin SJP; Russel-Szymczyk M; Psota M; Hlavinkova L; Hunt B
    Adv Ther; 2019 Aug; 36(8):2034-2051. PubMed ID: 31168765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of dulaglutide after switching from incretin-related drugs in patients with type 2 diabetes and inadequate glycemic control.
    Ito H; Araki R; Matsumoto S; Izutsu T; Kusano E; Kondo J; Inoue H; Antoku S; Yamasaki T; Mori T; Togane M
    Diabetol Int; 2022 Jan; 13(1):91-100. PubMed ID: 35059245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durability of protective effect of dulaglutide on pancreatic β-cells in diabetic mice: GLP-1 receptor expression is not reduced despite long-term dulaglutide exposure.
    Kimura T; Obata A; Shimoda M; Hirukawa H; Kanda-Kimura Y; Nogami Y; Kohara K; Nakanishi S; Mune T; Kaku K; Kaneto H
    Diabetes Metab; 2018 Jun; 44(3):250-260. PubMed ID: 29525225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11.
    Van J; Frias JP; Bonora E; Raha S; Meyer J; Jung H; Cox D; Konig M; Peleshok J; Bethel MA
    Diabetes Ther; 2021 Oct; 12(10):2783-2794. PubMed ID: 34514554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Uncommon Case of Dulaglutide-Related Morbilliform Drug Eruption.
    Kyriakos G; Diamantis E; Memi E; Elefsiniotis I
    Cureus; 2022 Jan; 14(1):e21536. PubMed ID: 35223310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
    Rosenstock J; Frias J; Jastreboff AM; Du Y; Lou J; Gurbuz S; Thomas MK; Hartman ML; Haupt A; Milicevic Z; Coskun T
    Lancet; 2023 Aug; 402(10401):529-544. PubMed ID: 37385280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetes.
    Edwards KL; Minze MG
    Core Evid; 2015; 10():11-21. PubMed ID: 25657615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Dulaglutide on Thyroid C Cells and Serum Calcitonin in Male Monkeys.
    Vahle JL; Byrd RA; Blackbourne JL; Martin JA; Sorden SD; Ryan T; Pienkowski T; Wijsman JA; Smith HW; Rosol TJ
    Endocrinology; 2015 Jul; 156(7):2409-16. PubMed ID: 25860028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide.
    Nauck MA; Frossard JL; Barkin JS; Anglin G; Hensley IE; Harper KD; Milicevic Z
    Diabetes Care; 2017 May; 40(5):647-654. PubMed ID: 28283565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.